Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Summary on Jun 27, 2018

June 27, 2018 - By Matthew Medley

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Corporate Logo

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Coverage

In total 3 analysts cover Adaptimmune Therapeutics (NASDAQ:ADAP). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 3 are the (NASDAQ:ADAP)’s analyst reports since March 16, 2018 according to StockzIntelligence Inc. In Friday, March 16 report Cowen & Co maintained the stock with “Buy” rating. On Friday, March 16 the rating was initiated by Leerink Swann with “Buy”. Listed here are Adaptimmune Therapeutics plc (NASDAQ:ADAP) PTs and latest ratings.

16/03/2018 Broker: Cowen & Co Rating: Buy Maintain
16/03/2018 Broker: Raymond James Rating: Buy New Target: $20.0
16/03/2018 Broker: Leerink Swann Rating: Buy New Target: $15.0 Initiate

The stock decreased 2.17% or $0.28 during the last trading session, hitting $12.61.Currently Adaptimmune Therapeutics plc is uptrending after 151.13% change in last June 27, 2017. ADAP has also 333,524 shares volume. ADAP outperformed the S&P 500 by 138.56%.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform.The firm is valued at $1.19 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients.Currently it has negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Another two news for Adaptimmune Therapeutics plc (NASDAQ:ADAP) were recently released by: on June 01, 2018 with title “Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler …”. The other‘s article was titled “Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self-renewing, and …” and released on June 11, 2018.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.